This study is for patients with neuroblastoma, a type of cancer that mostly affects children. The treatment involves two drugs: DFMO (Difluoromethylornithine) and etoposide. These drugs will be given together for six cycles over about four months, then just DFMO for about two more years. The goal is to see if this helps patients who have not responded to other treatments, or whose cancer has returned. Participants will be split into three groups based on their disease status: those with no active cancer, those who have relapsed but have no active cancer now, and those with active cancer.

• Duration: The study lasts over two years, with initial treatments and follow-ups.
• Eligibility: Patients up to 31 years old with a history of neuroblastoma can join.
• Risks and Considerations: Participants cannot be on other investigational drugs and should have no active infections.

If you participate, you will need to meet specific health criteria and agree to regular monitoring. This study requires a commitment, but it provides a chance to try new treatments. Discuss with your doctor to see if it's right for you.